Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

nespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to the further development and potential safety, efficacy, commercialization and other characteristics of Kosan's epothilone, KOS-1584[/R1645]; and initiations of clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of KOS-1584[/R1645], including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; Kosan's dependence on its collaboration with Roche for develo
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively ... June 8 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced results from a meta-analysis of cardiovascular (CV) ... with BYETTA(R) (exenatide) injection use compared to a pooled comparator ...
... Dose Optimization of Pre-Clinical Otelixizumab Surrogate , ... a biopharmaceutical company engaged in the discovery and ... presented results from a pre-clinical dose-optimization study conducted ... monoclonal antibody, otelixizumab, at the 69th Scientific Sessions ...
Cached Medicine Technology:Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/31/2015)... and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. ... , Glancing out of the window, he recalled that his equipment was set up ... Street tower, he jumped out of bed. , The photo speaks for itself. Chatfield ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. ... and post-acute care providers understand the benefits of using medication management technologies ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... “ Crack’em ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... make less mess while cooking. , Cooking can be a very messy experience, especially ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Make Less Mess while Cooking with Crack’em 2
... Hair with MilkSAN CLEMENTE, Calif., May 4 Maintaining strong, ... including Latinas. So when a new product comes on ... hair, many ladies jump on the bandwagon. The beauty ... more on hair care products than other Americans, according to ...
... Quality, for Company,s Medical DevicesPITTSBURGH, May 4 ... ), manufacturers of noninvasive medical evaluation equipment used ... other disorders, said today that it has earned ... and services.Nystagmography is the recording and measurement of ...
... new safety regulations, , , MONDAY, May 4 (HealthDay News) -- ... a mother. , Last March, her 2-year-old son and ... dressed in the bathroom. , Stevenson heard a crash. She ... lying on top of her daughter. Her son, Michael, was ...
... team of researchers at The National Cancer Center Hospital in ... lung cancer resection surgery between 2000 and 2006. The study ... of Thoracic Oncology , the official journal of the International ... his team found that after classifying patients based on the ...
... Others Question the Continuing Use of Mercury , WASHINGTON, ... Consumers for Dental Choice and the Mercury Policy Project, ... DHR ) corporation to transition out of manufacturing mercury ... Hotel in Washington D.C. this Tuesday, May 5 at ...
... The medical director for the Los Angeles Jewish ... in the western United States, today shared the Home,s ... for and precautions to take as fear of swine ... are very similar to that of the flu bugs ...
Cached Medicine News:Health News:Better Hair Days With Milk 2Health News:Better Hair Days With Milk 3Health News:Neuro Kinetics Earns ISO 13485 Certification 2Health News:More Kids Being Hurt by Falling Furniture 2Health News:More Kids Being Hurt by Falling Furniture 3Health News:Shareholders Challenge Danaher/Kerr to Phase Out Mercury Tooth Fillings 2Health News:Medical Director of Renowned Los Angeles Jewish Home Offers Advice to Seniors on Avoiding Swine Flu 2
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: